Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRISTOL MYERS SQUIBB COBMY · Entity 1662 | EVP,Chief Med.Offr.,Drug Dev. | April 25, 2025 | April 29, 2025 |
| Iambic Therapeutics, Inc.IAM · Entity 184417 | Director | October 14, 2026 | October 14, 2026 |
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Director | June 10, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRISTOL MYERS SQUIBB CO
Report date April 25, 2025 · Filed April 29, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.10 par valueSEC Table I · non-derivative | Direct | 83,513.486 |
Reported balance
After 2025-04-25 transaction · row 1
1 source rowRow 1 · 2025-04-25 · Purchase · Acquired 4,250 · Balance 83,513.486 |
Iambic Therapeutics, Inc.
Report date October 14, 2026 · Filed October 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.47 · Expires 2036-08-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-10-14 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Twenty-five percent of the shares subject to the option vest on August 10, 2027 and 1/48th of the shares vest monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Twenty-five percent of the shares subject to the option vest on August 10, 2027 and 1/48th of the shares vest monthly thereafter.
Pacira BioSciences, Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,405 |
Reported balance
After 2026-06-10 transaction · row 1
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 6,405 · Balance 6,405 F1: Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.42 · Expires 2036-06-10 | Direct | 10,891 |
Reported balance
After 2026-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-10 · Grant · Acquired 10,891 · Balance 10,891 F2: The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F2: The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 10, 2023 Filed Mar 15, 2023 00:18 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 3,069 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-23-000064 · wf-form4_167883950491167.xml · nonDerivative · entry 11 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,104 F7 · shares: Adjustment to Award based on the performance factor applied in accordance with the terms of the Award and certification of performance results by the Board. Read SEC document |
| March 10, 2023 Filed Mar 15, 2023 00:18 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 25,139 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-23-000064 · wf-form4_167883950491167.xml · nonDerivative · entry 10 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · shares: Amount represents distribution of performance shares earned under the 2020-2022 Long-Term Performance Award. Read SEC document |
| March 10, 2023 Filed Mar 15, 2023 00:18 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 2,517 | $65.71 | $165,392.07 |
DisclosureSEC source: 0000014272-23-000064 · wf-form4_167883950491167.xml · nonDerivative · entry 9 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,896 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2023 Filed Mar 15, 2023 00:18 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 154 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-23-000064 · wf-form4_167883950491167.xml · nonDerivative · entry 8 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,413 F2 · shares: Adjustment reflects additional shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 10, 2023 Filed Mar 15, 2023 00:18 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 4,765 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-23-000064 · wf-form4_167883950491167.xml · nonDerivative · entry 7 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Represents vesting of one-quarter of market share units granted on March 10, 2022. Read SEC document |
| March 10, 2023 Filed Mar 15, 2023 00:18 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 2,909 | $65.71 | $191,150.39 |
DisclosureSEC source: 0000014272-23-000064 · wf-form4_167883950491167.xml · nonDerivative · entry 6 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,494 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2023 Filed Mar 15, 2023 00:18 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 802 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-23-000064 · wf-form4_167883950491167.xml · nonDerivative · entry 5 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,403 F2 · shares: Adjustment reflects additional shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 10, 2023 Filed Mar 15, 2023 00:18 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 4,885 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-23-000064 · wf-form4_167883950491167.xml · nonDerivative · entry 4 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,601 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: Represents vesting of one-quarter of market share units granted on March 10, 2021. Read SEC document |
| March 10, 2023 Filed Mar 15, 2023 00:18 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 2,540 | $65.71 | $166,903.40 |
DisclosureSEC source: 0000014272-23-000064 · wf-form4_167883950491167.xml · nonDerivative · entry 3 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,716 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2023 Filed Mar 15, 2023 00:18 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 775 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-23-000064 · wf-form4_167883950491167.xml · nonDerivative · entry 2 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,256 F2 · shares: Adjustment reflects additional shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 10, 2023 Filed Mar 15, 2023 00:18 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 4,189 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-23-000064 · wf-form4_167883950491167.xml · nonDerivative · entry 1 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,481 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents vesting of one-quarter of market share units granted on March 10, 2020. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 20:28 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionRestricted Stock Units · Derivative | 9,356 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-22-000154 · wf-form4_165705285516489.xml · derivative · entry 3 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,357 Underlying: Common Stock, $0.10 par value · 9,356 shares Expires 2023-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · shares: The restricted stock units vest in four equal installments beginning on July 1, 2020. F1 · derivative.exercise_date: The restricted stock units vest in four equal installments beginning on July 1, 2020. F1 · derivative.expiration_date: The restricted stock units vest in four equal installments beginning on July 1, 2020. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 20:28 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 4,786 | $76.84 | $367,756.24 |
DisclosureSEC source: 0000014272-22-000154 · wf-form4_165705285516489.xml · nonDerivative · entry 2 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,292 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock units. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 20:28 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 9,356 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-22-000154 · wf-form4_165705285516489.xml · nonDerivative · entry 1 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,078 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The restricted stock units vest in four equal installments beginning on July 1, 2020. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:17 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 28,593 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-22-000072 · wf-form4_164730701224878.xml · derivative · entry 10 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,593 Underlying: Common Stock, $0.10 par value · 28,593 shares Expires 2025-03-10 F7 · derivative.exercise_price: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2025. F7 · derivative.exercise_date: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2025. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:17 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantMarket Share Units · Derivative | 19,062 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-22-000072 · wf-form4_164730701224878.xml · derivative · entry 9 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,062 Underlying: Common Stock, $0.10 par value · 19,062 shares Expires 2026-03-10 F5 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F6 · derivative.exercise_date: Twenty-five percent of these market share units will vest on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:17 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 4,885 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-22-000072 · wf-form4_164730701224878.xml · derivative · entry 8 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,656 Underlying: Common Stock, $0.10 par value · 4,885 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F4 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 10, 2021. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:17 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 4,189 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-22-000072 · wf-form4_164730701224878.xml · derivative · entry 7 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,381 Underlying: Common Stock, $0.10 par value · 4,189 shares Expires 2024-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F1 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 10, 2020. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:17 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 2,779 | $68.42 | $190,139.18 |
DisclosureSEC source: 0000014272-22-000072 · wf-form4_164730701224878.xml · nonDerivative · entry 6 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,722 F3 · shares: Shares withheld for payment of taxes upon vesting of award. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:17 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 548 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-22-000072 · wf-form4_164730701224878.xml · nonDerivative · entry 5 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,501 F2 · shares: Adjustment reflects additional shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:17 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 4,885 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-22-000072 · wf-form4_164730701224878.xml · nonDerivative · entry 4 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,953 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: Represents vesting of one-quarter of market share units granted on March 10, 2021. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:17 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 2,426 | $68.42 | $165,986.92 |
DisclosureSEC source: 0000014272-22-000072 · wf-form4_164730701224878.xml · nonDerivative · entry 3 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,068 F3 · shares: Shares withheld for payment of taxes upon vesting of award. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:17 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 553 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-22-000072 · wf-form4_164730701224878.xml · nonDerivative · entry 2 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,494 F2 · shares: Adjustment reflects additional shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:17 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 4,189 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-22-000072 · wf-form4_164730701224878.xml · nonDerivative · entry 1 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents vesting of one-quarter of market share units granted on March 10, 2020. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:38 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionRestricted Stock Units · Derivative | 9,356 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-21-000182 · wf-form4_162560392359905.xml · derivative · entry 3 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,713 Underlying: Common Stock, $0.10 par value · 9,356 shares Expires 2023-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · derivative.exercise_date: The restricted stock unit vests in four equal installments beginning on July 1, 2020. F1 · derivative.expiration_date: The restricted stock unit vests in four equal installments beginning on July 1, 2020. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:38 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 4,786 | $66.56 | $318,556.16 |
DisclosureSEC source: 0000014272-21-000182 · wf-form4_162560392359905.xml · nonDerivative · entry 2 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,752 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock units. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:38 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 9,356 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-21-000182 · wf-form4_162560392359905.xml · nonDerivative · entry 1 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,538 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The restricted stock unit vests in four equal installments beginning on July 1, 2020. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 23:56 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 29,311 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-21-000091 · wf-form4_161559336318038.xml · derivative · entry 6 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,311 Underlying: Common Stock, $0.10 par value · 29,311 shares Expires 2024-03-10 F6 · derivative.exercise_price: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2024. F6 · derivative.exercise_date: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2024. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 23:56 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantMarket Share Units · Derivative | 19,541 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-21-000091 · wf-form4_161559336318038.xml · derivative · entry 5 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,541 Underlying: Common Stock, $0.10 par value · 19,541 shares Expires 2025-03-10 F4 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F5 · derivative.exercise_date: Twenty-five percent of these market share units will vest on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 23:56 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 4,189 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-21-000091 · wf-form4_161559336318038.xml · derivative · entry 4 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,570 Underlying: Common Stock, $0.10 par value · 4,189 shares Expires 2024-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F1 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 10, 2020. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 23:56 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 1,978 | $60.93 | $120,519.54 |
DisclosureSEC source: 0000014272-21-000091 · wf-form4_161559336318038.xml · nonDerivative · entry 3 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,182 F3 · shares: Shares withheld for payment of taxes upon vesting. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 23:56 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 78 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-21-000091 · wf-form4_161559336318038.xml · nonDerivative · entry 2 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,160 F2 · shares: Adjustment reflects additional shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 23:56 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 4,189 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-21-000091 · wf-form4_161559336318038.xml · nonDerivative · entry 1 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,082 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents vesting of one-quarter of market share units granted on March 10, 2020. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:56 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionRestricted Stock Units · Derivative | 9,356 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-20-000211 · wf-form4_159372332690183.xml · derivative · entry 3 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,069 Underlying: Common Stock, $0.10 par value · 9,356 shares Expires 2023-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on July 1, 2020. F1 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on July 1, 2020. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:56 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 4,463 | $59.43 | $265,236.09 |
DisclosureSEC source: 0000014272-20-000211 · wf-form4_159372332690183.xml · nonDerivative · entry 2 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,893 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock units. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:56 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 9,356 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-20-000211 · wf-form4_159372332690183.xml · nonDerivative · entry 1 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The restricted stock units vest in four equal annual installments beginning on July 1, 2020. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 22:15 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 25,139 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-20-000121 · wf-form4_158405129192763.xml · derivative · entry 2 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,139 Underlying: Common Stock, $0.10 par value · 25,139 shares Expires 2023-03-10 F3 · derivative.exercise_price: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2023. F3 · derivative.exercise_date: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2023. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 22:15 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantMarket Share Units · Derivative | 16,759 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-20-000121 · wf-form4_158405129192763.xml · derivative · entry 1 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,759 Underlying: Common Stock, $0.10 par value · 16,759 shares Expires 2024-03-10 F1 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F2 · derivative.exercise_date: Twenty-five percent of these market share units will vest on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 17:35 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantRestricted Stock Units · Derivative | 37,425 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-19-000149 · wf-form4_156217532599648.xml · derivative · entry 1 Hirawat Samit · CIK 0001781290 · Chief Medical Offr., Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,425 Underlying: Common Stock, $0.10 par value · 37,425 shares Expires 2023-07-01 F1 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on July 1, 2020. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on July 1, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.